Research groups
Websites
-
MRC Molecular Haematology Unit
Research Unit
-
MRC Weatherall Institute of Molecular Medicine
Research Institute
-
Oxford Centre for Haematology
Virtual Centre
-
National Institute for Health Research
Senior Fellow
Paresh Vyas
MRCP FRCP FRCPath
Professor of Haematology
- Consultant Physician
Normal and Leukaemic stem/progenitor cell biology
Our aim is to characterise the heterogeneous populations of leukaemia propagating cells in adult and childhood Acute Myeloid Leukaemia (AML) at functional, genetic, epigenetic and molecular levels, eventually at a single cell level, to improve our basic understanding of leukaemia initiation and propagation. The ultimate aim is to translate this knowledge to improve survival rates in patients.
Biography
Paresh Vyas is Professor of Haematology at the University of Oxford. He studied medicine at Cambridge then Oxford. After completing his medical and haematology training in London, he did his PhD with Professor Doug Higgs and Professor Sir David Weatherall at the MRC Molecular Haematology Unit, Oxford. A three-year post-doctoral fellowship with Professor Stuart Orkin at Harvard University followed. He is a research-active Consultant Haematologist with a clinical practice in myeloid disorders: myelodysplastic syndrome, MDS, acute myeloid leukaemia, AML, and myeloproliferative disorders, MPD, as well as allogeneic stem cell transplant. His research in the MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, focuses on molecular and cellular biology of AML and MDS with specific interest in purification and therapeutic targeting of myeloid stem cells. He studies single cell biology in normal and leukaemic haemopoiesis. He is on the UK AML and MDS clinical trial groups. He is co-Lead of the Oxford BRC Haematology and Stem Cells Theme, is on the Board of NHSBT, vice-chair of the MRC Clinical Training Panel and Translational Lead for the UK Therapy Acceleration Program.
Key publications
-
Journal article
Di Genua C. et al, (2020), Cancer Cell, 37, 690 - 704.e8
-
Journal article
Labuhn M. et al, (2019), Cancer Cell, 36, 123 - 138.e10
-
Journal article
Quek L. et al, (2018), Nat Med, 24, 1167 - 1177
-
Journal article
Karamitros D. et al, (2018), Nat Immunol, 19, 85 - 97
-
Journal article
Quek L. et al, (2016), J Exp Med, 213, 1513 - 1535
-
Journal article
Goardon N. et al, (2011), Cancer Cell, 19, 138 - 152
Recent publications
-
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
Journal article
Sekeres MA. et al, (2022), Ann Hematol
-
Shall We Dance: Evolving Partnerships of Targeted Therapies for AML.
Journal article
Perl AE. and Vyas P., (2022), Clin Cancer Res
-
Genetic and non-genetic mechanisms of inflammation may promote transformation in leukemia.
Journal article
Vyas P., (2022), Cell Stem Cell, 29, 184 - 186
-
Identification and Preliminary Structure-Activity Relationship Studies of 1,5-Dihydrobenzo[e][1,4]oxazepin-2(3H)-ones That Induce Differentiation of Acute Myeloid Leukemia Cells In Vitro.
Journal article
Josa-Culleré L. et al, (2021), Molecules, 26
-
A Phenotypic Screen Identifies a Compound Series That Induces Differentiation of Acute Myeloid Leukemia Cells In Vitro and Shows Antitumor Effects In Vivo.
Journal article
Josa-Culleré L. et al, (2021), J Med Chem